Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Kushi Kullar who wrote (8781)	2/19/1999 10:18:00 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

From XOMA backgrounders, "peptidomimetics" For more info. see this URL. far.ruu.nl Partial preview of what's there: Let me hype this post, DON'T FAIL TO VIST THE URL!!!!!!!!! Peptide-protein interactions Often peptides and proteins have a signalling role in immunological and/or neurological processes. The medicinal group investigates these interactions of peptides with proteins. These signalling molecules are major players in many chronic and infectious diseases, for which no therapy is known. Utrecht University houses much expertise in this field of research. The approach followed mainly relies on converting peptides to peptidomimetic compounds and investigating the consequences for protein interaction. Peptidomimetics often are more stable and less easily cleared from the blood stream than peptides. Since this modification should not decrease the affinity, quite a detailed three-dimensional understanding of the interaction is of the utmost importance. Peptidomimetics should mimic these peptides as closely as possible. Non-peptide lead compounds from biogenic origin also serve as nature's solution to a particular problem. The natural diversity aiming at a certain target is further mimicked by combinatorial libraries. A molecular microscope is offered by molecular modelling and biophysical experiments to stimulate the (bio)synthesis of new mimics.